On July 17, MicroPort Scientific declined 6.74% in regular trading, trading at HK$6.64/share, with turnover of HK$117 million. The stock gave back prior-session gains as market divergence intensified following the announcement of a planned orthopedics asset disposal.
On July 15, the company disclosed that its subsidiary Suzhou MicroPort Orthopedics signed a letter of intent with Tinavi Medical Technologies to sell its 82.29% stake in Shanghai MicroPort Orthopedics, with consideration to be paid via issuance of new Tinavi shares. Shanghai MicroPort Orthopedics is the group's core international orthopedics platform, operating in the US, Japan, and Europe with over one million cumulative hip and knee implant cases.
After an initial rally of over 6% on July 16, sentiment reversed as concerns mounted. Bears argue the sale of a core overseas asset signals debt repayment pressure and potential half-year earnings weakness. Additionally, Tinavi — a yet-to-profit STAR Market company with revenue of only RMB 279 million — raises uncertainty over the realizable value of the share-based consideration.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments